Long-Lasting Complete Intracranial Response to Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

The case describes a patient with HER2-positive breast cancer whose disease had spread to the brain, with more than 20 active brain metastases documented on imaging. Age, sex, and detailed histologic subtype beyond HER2-positive status are not reported in the source. No formal TNM stage was assigned; the disease is described as metastatic with active, multiple brain lesions at the time of the events described.

The source reports that the patient had multiple (more than 20) active brain metastases from HER2-positive breast cancer. Specific presenting neurological symptoms are not detailed beyond the later note that neurological symptoms improved once intracranial disease responded to treatment, implying some degree of neurological symptom burden was present beforehand. No further presenting complaints or examination findings are described.

HER2 positivity was established, though the specific testing method (immunohistochemistry or in situ hybridization) is not reported. Brain imaging identified more than 20 active metastatic lesions. No additional histologic subtyping or formal TNM staging is documented in the source.

The patient received whole-brain radiotherapy (WBRT) together with trastuzumab emtansine (T-DM1), an antibody-drug conjugate combining trastuzumab with a cytotoxic payload, for HER2-positive brain metastases. After intracranial progression on this regimen, third-line treatment with trastuzumab deruxtecan (T-DXd), a different HER2-targeted antibody-drug conjugate, was initiated.

Following WBRT and T-DM1, the patient developed intracranial progression, meaning the brain metastases grew or new lesions appeared despite treatment. After switching to T-DXd, imaging showed a complete radiological response within the brain, meaning no residual detectable disease was seen on the scans used to assess the intracranial lesions.

The complete intracranial response to T-DXd was maintained for more than 20 months while the patient continued therapy. Over this period, the source reports improvement in neurological symptoms and in quality of life. No further follow-up beyond this point is described.

The central finding - a complete and durable intracranial response to T-DXd after failure of WBRT and T-DM1 - sits within a body of evidence that supports T-DXd's capacity to produce meaningful CNS responses in HER2-positive breast cancer, but that evidence does not fully resolve why this particular response was so extensive and long-lasting. Prospective trial data in closely matching populations, including a phase 2 trial enrolling patients with active brain metastases, document intracranial response rates and some responses sustained beyond a year, providing a real but imperfect benchmark for this patient's more than 20-month response. The mechanistic account most often proposed - that T-DXd's chemotherapy payload produces a bystander cytotoxic effect against HER2-heterogeneous tumor cells after crossing a disrupted blood-brain barrier - is supported by in vitro and xenograft data showing bystander killing of HER2-low neighboring cells, but the CNS-specific step of that account, whether the released payload diffuses effectively once inside brain tissue, has not been directly demonstrated and is contested by reviews arguing that barrier integrity, not disruption, remains the dominant constraint on drug delivery to CNS metastases. The relationship between this patient's earlier T-DM1 resistance and later T-DXd sensitivity is consistent with population-level trial data showing T-DXd retains activity after T-DM1 progression, but the specific resistance mechanism operating in this patient's tumor was not characterized, so the case illustrates a pattern documented in trials rather than a mechanism verified in this individual.

Read narrowly, this case documents a favorable clinical outcome: intracranial progression on an older HER2-targeted antibody-drug conjugate followed by a complete and unusually durable response to a newer one. Read against the wider evidence base, several open questions temper how far that outcome can be generalized. Whether the blood-brain barrier disruption present across this patient's more than twenty lesions was sufficient and sufficiently uniform to allow adequate T-DXd delivery to all of them is not something this case, or the cited preclinical literature, can settle; barrier permeability in brain metastasis models is reported as markedly heterogeneous, with some regions retaining near-normal barrier function despite radiographic enhancement, and clinical reviews of HER2-positive CNS disease differ on how much this heterogeneity limits drug delivery in practice. The bystander cytotoxic mechanism proposed to explain activity against HER2-heterogeneous lesions has firmer support in cell-based and xenograft systems than in the CNS specifically; a review addressing CNS pharmacodynamics for T-DXd raises the possibility that free payload diffusion within brain tissue after crossing a partially disrupted barrier may behave differently than in peripheral tumors. Prior WBRT could plausibly have altered barrier integrity in ways relevant to later ADC penetration, since radiation-induced endothelial and tight-junction changes are documented mechanistically, but animal data also indicate such barrier effects can be transient, fading over weeks to months, and because the interval between this patient's WBRT and T-DXd initiation is not reported, no conclusion about whether radiation contributed to later drug delivery can be drawn from this case. Finally, while trial-level evidence supports a general lack of complete cross-resistance between T-DM1 and T-DXd, consistent with this patient responding to T-DXd after T-DM1 failure, none of the cited evidence characterizes the resistance mechanism actually present in this patient's tumor, so the case is best read as one instance consistent with a documented population-level pattern rather than a mechanistically resolved account of an individual response.

As a single case, this report cannot establish how representative the more than 20-month complete intracranial response is, nor can it control for other factors - such as systemic disease status, concurrent supportive care, or unmeasured tumor characteristics - that might have contributed to the outcome. Neither the timing between WBRT and T-DM1 nor the interval before T-DXd initiation is reported, limiting assessment of whether radiation effects on the blood-brain barrier remained active when T-DXd was started. No post-progression or post-response biopsy of brain lesions is described, so proposed mechanisms remain inferred from separate preclinical and trial populations rather than confirmed in this patient's own tissue. This analysis is a secondary synthesis restricted to a defined set of supplied evidence items and does not represent an exhaustive systematic review of the broader literature on T-DXd in HER2-positive CNS disease.

The source notes that the patient experienced improvement in neurological symptoms and quality of life over the more than 20 months of sustained intracranial response, but no direct patient account or quality-of-life measurement instrument is described in the available report.